Sugi Predict

Sugi Predict / Compounds / SCHEMBL1494549

SCHEMBL1494549

SCHEMBL1494549

Cc1c(N)cc(Cl)cc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 5/20 0.43
▸ ALDH1A1 P00352 5/20 0.37
▸ TSHR P16473 4/20 0.37
▸ ALOX15 P16050 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ TP53 P04637 2/20 0.36
▸ CD44 P16070 1/20 0.36
▸ MAPK1 P28482 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CASP7 P55210 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ NR4A2 P43354 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ERN1 O75460 1/20 0.32
▸ CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12535917 0.82 TSHR (0.41) CYP3A4ALDH1A1TSHRSMN1; SMN2TP53
SCHEMBL3671147 0.82 CYP3A4 (0.52) CYP3A4ALDH1A1TSHRALOX15SMN1; SMN2
SCHEMBL17057702 0.76 CYP3A4 (0.34) CYP3A4ALDH1A1TSHRALOX15SMN1; SMN2
SCHEMBL30627393 0.76 CYP3A4 (0.34) CYP3A4ALDH1A1TSHRALOX15SMN1; SMN2
SCHEMBL10495441 0.75 ALDH1A1 (0.41) CYP3A4ALDH1A1TSHRTP53HSD17B10
SCHEMBL31150405 0.75 CYP3A4 (0.45) CYP3A4ALDH1A1TSHRALOX15SMN1; SMN2
SCHEMBL22232536 0.75 ALDH1A1 (0.41) CYP3A4ALDH1A1TSHRALOX15SMN1; SMN2
SCHEMBL29678010 0.75 ALDH1A1 (0.41) CYP3A4ALDH1A1TSHRALOX15SMN1; SMN2
SCHEMBL12925873 0.75 CES1 (0.36) CYP3A4ALDH1A1TSHRSMN1; SMN2GAA
SCHEMBL1494521 0.75 CYP3A4 (0.45) CYP3A4ALDH1A1TSHRALOX15SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688788-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS Pfizer Inc. (US) 2026-02-11 — — EP disclosed
EP-4646108-A1 TERNARY COMPOSITION COMPRISING 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 — — EP disclosed
US-12281127-B2 Pyrido[4,3-d]pyrimidine compounds PFIZER INC. (US) 2025-04-22 — — US disclosed
US-20250034173-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2025-01-30 — — US disclosed
US-20240336631-A1 Pyrido[4,3-d]pyrimidine Compounds PFIZER INC. (US) 2024-10-10 — — US disclosed
WO-2024209339-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2024-10-10 — — WO disclosed
WO-2024147155-A1 TERNARY COMPOSITION COMPRISING 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS AND USE THEREOF PI INDUSTRIES LTD. (IN) 2024-07-11 — — WO disclosed
CN-115724802-A Thiazolidine compound and application thereof 复旦大学 2023-03-03 — — CN disclosed
US-20180148429-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2018-05-31 — — US disclosed
US-8859548-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS AG (CH) 2014-10-14 — — US disclosed
EP-2470528-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2014-10-01 — — EP disclosed
US-20140011825-A1 Compounds and Compositions as Protein Kinase Inhibitors NOVARTIS AG (CH) 2014-01-09 — — US disclosed
US-8563553-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS AG (CH) 2013-10-22 — — US disclosed
US-20120225899-A1 Compounds and Compositions as Protein Kinase Inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-09-06 — — US disclosed
US-8242260-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS AG (CH) 2012-08-14 — — US disclosed
EP-2470528-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS Novartis AG (CH) 2012-07-04 — — EP disclosed
WO-2011023773-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-03-03 — — WO disclosed
US-20110052578-A1 Compounds and Compositions as Protein Kinase Inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110052578-A1 Compounds and Compositions as Protein Kinase Inhibitors RAF1, BRAF, ARAF CYP3A4 3580/4885ALDH1A1 3869/4885TSHR 1294/4885
US-20240336631-A1 Pyrido[4,3-d]pyrimidine Compounds DPYD, PNPO, TYMP CYP3A4 144/4885ALDH1A1 436/4885TSHR 3446/4885
US-12281127-B2 Pyrido[4,3-d]pyrimidine compounds DPYD, PNPO, TYMP CYP3A4 144/4885ALDH1A1 436/4885TSHR 3446/4885
US-20120225899-A1 Compounds and Compositions as Protein Kinase Inhibitors RAF1, BRAF, ARAF CYP3A4 3580/4885ALDH1A1 3869/4885TSHR 1294/4885
US-20250034173-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS DPYD, PNPO, TYMP CYP3A4 144/4885ALDH1A1 436/4885TSHR 3446/4885
US-20180148429-A1 SUBSTITUTED QUINOXALINE DERIVATIVES BRCA1, NQO2, NQO1 CYP3A4 2190/4885ALDH1A1 1674/4885TSHR 4313/4885
US-20140011825-A1 Compounds and Compositions as Protein Kinase Inhibitors RAF1, BRAF, ARAF CYP3A4 3580/4885ALDH1A1 3869/4885TSHR 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.